Novai
Francesca Cordeiro's work experience includes serving as a Board Trustee at Fight for Sight since July 2016. Francesca is also the Founder, Director, and CSO of Novai, a British biotechnology start-up focusing on commercializing DARC Technology for retinal biomarkers. Francesca has been in this role since February 2020. Francesca is an Honorary Consultant Ophthalmologist at St Marys Hospital NHS Trust since November 2005. Francesca has been a UCL Professor of Glaucoma and Retinal Neurodegeneration Studies at University College London since November 2001. Additionally, they have been the Chair of Ophthalmology at Imperial College London since January 2017.
Francesca Cordeiro began their education journey in 1982 at St Bartholomew's Hospital in London, where they pursued a degree in medicine. Francesca successfully completed their MBBS degree in 1987. In 1990, Francesca enrolled at the Royal College of Physicians in London to further enhance their medical knowledge and received an MRCP degree. Following this, in 1992, they joined the Royal College of Ophthalomolgists, where they pursued additional qualifications in the field. In 1998, Francesca embarked on a Doctor of Philosophy (Ph.D.) program at UCL, focusing on a specific area of study that is not mentioned in the provided information. Although the end year for their Ph.D. program is not mentioned, they are currently engaged in their doctoral studies.
This person is not in any teams
Novai
Novai is a British biotechnology start-up, commercialising DARC Technology, an exploratory retinal biomarker for use in Age-related Macular Degeneration (AMD) & glaucoma clinical studies. DARC combines an innovative patented biologic with a state-of-the-art AI algorithm and uses standard imaging equipment to identify cellular level diseaseactivity. DARC Technology can be used to measure the impact of current and future therapeutics and interventions by assessment of disease activity whilst identifying non-responders to existing and new interventions, resulting in the avoidance of costly, ineffective or un-required medical management. DARC helps to stratify patients in clinical trials, resulting in the creation of enriched patient cohorts, consisting of those at highest risk of rapid disease progression.DARC has been developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding and is now approved as an exploratory biomarker by the FDA & MHRA. Following further analysis of Phase II data, several other indications may follow, including Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Diabetes Mellitus and Cancer.